CDK2 and cancer: Thus, our study showed that the STAT3/CDK2/4/6 signature not only regulates immune cell infiltration but also affects the benefit for cancer patients of immune checkpoint blockade and provides a rationale for the combination of STAT3/CDK2/4/6 antagonist and immunological checkpoint inhibitors.